Breast Carcinoma — Trials

Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 873
Recruiting: 478
Ph III recruiting: 55
Growth YoY: −1.7%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 40.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (365)

clinicaltrialsPublishedShowing 451–500 of 2,394 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07669610	An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC(TRIBE)	not yet recruiting	Phase 3	140	Fudan UniversityOTHER	0	Jun 25, 2026	clinicaltrials
NCT02750358	Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer	active not recruiting	Phase 2	50	Memorial Sloan Kettering Cancer CenterOTHER	1	Jun 24, 2026